463 related articles for article (PubMed ID: 24838514)
21. Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors.
Tarasenko N; Chekroun-Setti H; Nudelman A; Rephaeli A
J Cell Biochem; 2018 Apr; 119(4):3417-3428. PubMed ID: 29135083
[TBL] [Abstract][Full Text] [Related]
22. Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy.
Spiegel S; Milstien S; Grant S
Oncogene; 2012 Feb; 31(5):537-51. PubMed ID: 21725353
[TBL] [Abstract][Full Text] [Related]
23. HDAC inhibitor Vorinostat and BET inhibitor Plx51107 epigenetic agents' combined treatments exert a therapeutic approach upon acute myeloid leukemia cell model.
Alcitepe İ; Salcin H; Karatekin İ; Kaymaz BT
Med Oncol; 2022 Oct; 39(12):257. PubMed ID: 36224430
[TBL] [Abstract][Full Text] [Related]
24. Romidepsin: a novel histone deacetylase inhibitor for cancer.
Bertino EM; Otterson GA
Expert Opin Investig Drugs; 2011 Aug; 20(8):1151-8. PubMed ID: 21699444
[TBL] [Abstract][Full Text] [Related]
25. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
26. Targeting histone deacetylases: development of vorinostat for the treatment of cancer.
Richon VM
Epigenomics; 2010 Jun; 2(3):457-65. PubMed ID: 22121904
[TBL] [Abstract][Full Text] [Related]
27. Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.
Bieliauskas AV; Weerasinghe SV; Negmeldin AT; Pflum MK
Arch Pharm (Weinheim); 2016 May; 349(5):373-82. PubMed ID: 27062198
[TBL] [Abstract][Full Text] [Related]
28. Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines.
Sarcar B; Kahali S; Chinnaiyan P
J Neurooncol; 2010 Sep; 99(2):201-7. PubMed ID: 20135194
[TBL] [Abstract][Full Text] [Related]
29. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
LaBonte MJ; Wilson PM; Fazzone W; Groshen S; Lenz HJ; Ladner RD
BMC Med Genomics; 2009 Nov; 2():67. PubMed ID: 19948057
[TBL] [Abstract][Full Text] [Related]
30. Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells.
Was H; Krol SK; Rotili D; Mai A; Wojtas B; Kaminska B; Maleszewska M
Clin Epigenetics; 2019 Jan; 11(1):11. PubMed ID: 30654849
[TBL] [Abstract][Full Text] [Related]
31. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C
Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373
[TBL] [Abstract][Full Text] [Related]
32. Early prediction of response to Vorinostat in an orthotopic rat glioma model.
Wei L; Hong S; Yoon Y; Hwang SN; Park JC; Zhang Z; Olson JJ; Hu XP; Shim H
NMR Biomed; 2012 Sep; 25(9):1104-11. PubMed ID: 22302519
[TBL] [Abstract][Full Text] [Related]
33. Revisiting Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients with Glioblastoma-Proteomic Alteration and Comparison Analysis with the Standard-of-Care Chemoirradiation.
Krauze AV; Zhao Y; Li MC; Shih J; Jiang W; Tasci E; Cooley Zgela T; Sproull M; Mackey M; Shankavaram U; Tofilon P; Camphausen K
Biomolecules; 2023 Oct; 13(10):. PubMed ID: 37892181
[TBL] [Abstract][Full Text] [Related]
34. Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer.
Ren Y; Li S; Zhu R; Wan C; Song D; Zhu J; Cai G; Long S; Kong L; Yu W
J Med Chem; 2021 Jun; 64(11):7468-7482. PubMed ID: 34043359
[TBL] [Abstract][Full Text] [Related]
35. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
[TBL] [Abstract][Full Text] [Related]
36. Histone deacetylase inhibitors and colorectal cancer: what is new?
Tampakis A; Tampaki EC; Nebiker CA; Kouraklis G
Anticancer Agents Med Chem; 2014; 14(9):1220-7. PubMed ID: 25246306
[TBL] [Abstract][Full Text] [Related]
37. Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities.
Dedes KJ; Dedes I; Imesch P; von Bueren AO; Fink D; Fedier A
Anticancer Drugs; 2009 Jun; 20(5):321-33. PubMed ID: 19322073
[TBL] [Abstract][Full Text] [Related]
38. Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma.
Kavanaugh SM; White LA; Kolesar JM
Am J Health Syst Pharm; 2010 May; 67(10):793-7. PubMed ID: 20479100
[TBL] [Abstract][Full Text] [Related]
39. The Search for Potent, Small-Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat.
Zagni C; Floresta G; Monciino G; Rescifina A
Med Res Rev; 2017 Nov; 37(6):1373-1428. PubMed ID: 28181261
[TBL] [Abstract][Full Text] [Related]
40. The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity.
Choi SE; Weerasinghe SV; Pflum MK
Bioorg Med Chem Lett; 2011 Oct; 21(20):6139-42. PubMed ID: 21889343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]